Back to Search Start Over

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

Source :
Plus Company Updates. December 23, 2022
Publication Year :
2022

Abstract

CELEBRATION, Fla: KemPharm has issued the following news release: KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Plus Company Updates
Publication Type :
News
Accession number :
edsgcl.731282688